Financial News
Articles published by Femasys Inc.
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
November 12, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys to Exhibit at the Annual AAGL 2024 Global Conference
November 07, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
November 01, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed
October 30, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
October 10, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
October 08, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Announces Infertility Clinic Customers from Coast to Coast
September 18, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
September 11, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
September 09, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting
September 05, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
August 29, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
August 27, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
August 08, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council
May 16, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
May 09, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
March 28, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
March 13, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
March 06, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
February 28, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
February 06, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers
FEMY
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.